...
机译:相IB / II研究低剂量去染色的耐药复后/难治性消化道癌症患者的低剂量脱蛋白灌注疗效性和疗效研究
Department of Molecular Biology and Bio‐therapeuticInstitute of Basic Medicine Chinese PLA General;
Department of Molecular Biology and Bio‐therapeuticInstitute of Basic Medicine Chinese PLA General;
Department of Molecular Biology and Bio‐therapeuticInstitute of Basic Medicine Chinese PLA General;
Department of Molecular Biology and Bio‐therapeuticInstitute of Basic Medicine Chinese PLA General;
Department of Molecular Biology and Bio‐therapeuticInstitute of Basic Medicine Chinese PLA General;
Department of SurgeryJohns Hopkins UniversityBaltimore MD;
Department of Molecular Biology and Bio‐therapeuticInstitute of Basic Medicine Chinese PLA General;
Department of Molecular Biology and Bio‐therapeuticInstitute of Basic Medicine Chinese PLA General;
Department of Molecular Biology and Bio‐therapeuticInstitute of Basic Medicine Chinese PLA General;
Department of Molecular Biology and Bio‐therapeuticInstitute of Basic Medicine Chinese PLA General;
Department of Molecular Biology and Bio‐therapeuticInstitute of Basic Medicine Chinese PLA General;
Department of Gastroenterology and HepatologyChinese PLA General HospitalBeijing People's Republic;
Department of Molecular Biology and Bio‐therapeuticInstitute of Basic Medicine Chinese PLA General;
Department of Molecular Biology and Bio‐therapeuticInstitute of Basic Medicine Chinese PLA General;
alimentary tract cancer; relapsed/refractory; hypomethylation agent; drug resistance; chemoimmunotherapy;
机译:相IB / II研究低剂量去染色的耐药复后/难治性消化道癌症患者的低剂量脱蛋白灌注疗效性和疗效研究
机译:尼罗替尼在日本伊马替尼耐药或难治性Ph + CML或复发/难治性Ph + ALL患者中的疗效和安全性:I和II期研究的36个月分析。
机译:尼罗替尼在日本伊马替尼耐药或难治性Ph + CML或复发/难治性Ph + ALL患者中的疗效和安全性:一项I和II期研究的36个月分析
机译:需要肺泡成纤维细胞的下呼吸道感染药物耐药患者的评估标准:碳纳米管束缚成纤维细胞防御与患者耐药性之间的匹配:NIDHI标准
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:Ib / II期小剂量地西他滨为基础的化学免疫疗法在耐药性复发/难治性消化道癌症患者中的安全性和有效性研究
机译:相IB / II研究低剂量去染色/难治消化道癌症患者低剂量脱蛋白灌注疗效的安全性和疗效研究